2021 年全球肺癌治疗全景。
The 2021 Global Lung Cancer Therapy Landscape.
机构信息
Department of Biomedical Engineering, Columbia University, New York, New York.
LUNGevity Foundation, Chicago, Illinois.
出版信息
J Thorac Oncol. 2022 Jul;17(7):931-936. doi: 10.1016/j.jtho.2022.03.018. Epub 2022 Apr 27.
INTRODUCTION
The lung cancer treatment landscape has substantially evolved over the past decade. However, a systematic analysis of the current global drug development landscape has not been conducted.
METHODS
We curated and analyzed a comprehensive list of therapeutic entities (TEs) in preclinical development and clinical trials for lung cancer.
RESULTS
On the basis of our analysis of 707 TEs, we found a consistent forward trajectory in the development pipeline for both NSCLC and SCLC. Most of the TEs were in the advanced stages of clinical trials. Targeted therapies continue to dominate in the non-immuno-oncology space. Immuno-oncology targets are expanding beyond inhibitors of the programmed death-ligand 1 axis.
CONCLUSIONS
Our analysis highlights a robust portfolio of both preclinical and clinical TEs and suggests that lung cancer treatment is going to become even more biomarker-driven.
简介
在过去的十年中，肺癌治疗领域发生了重大变化。然而，目前还没有对全球药物研发领域进行系统分析。
方法
我们整理和分析了肺癌临床前开发和临床试验中治疗实体（Therapeutic Entities，TEs）的综合清单。
结果
基于对 707 个 TEs 的分析，我们发现非小细胞肺癌（NSCLC）和小细胞肺癌（SCLC）的开发管道都呈现出持续向前发展的趋势。大多数 TEs 处于临床试验的后期阶段。靶向治疗在非免疫肿瘤学领域继续占据主导地位。免疫肿瘤学的靶点正在超越程序性死亡配体 1 轴抑制剂的范围。
结论
我们的分析突出了大量的临床前和临床 TEs，并表明肺癌治疗将变得更加依赖生物标志物。
Zotero 插件